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Summary 
Among HIV+ patients an increasing number of people acquire a co-infection with the 
hepatitits C virus (HCV). Compared to HCV mono-infected patients, the HCV co-infec-
tion in HIV+ patients leads to accelerated rates of fibrosis and liver associated morbid-
ity and mortality. Regardless of the pre-existing HIV infection a small proportion of the 
co-infected patients clear their acute HCV infection naturally in the early stage before 
establishing a chronic infection. In our studies, we investigated the role of natural killer 
cells (NK cells) as well as natural killer-like T cells (NK-like T cells) in modulating out-
comes of acute hepatitis C infection in HIV+ patients. Patients with chronic HCV/HIV 
co-infection, HIV mono infection, as well as healthy individuals were studied as con-
trols. NK- and NK-like T cells were studied phenotypically and functionally by flowcy-
tometric analysis. Interferon-gamma (IFN-g) secretion, degranulation (CD107a) and 
anti-HCV activity were studied using the Huh7-HCVreplicon cells system. NK- and NK-
like T cell frequency did not vary significantly with respect to outcome of acute HCV 
infection. Nevertheless, in vitro NK cells from patients with a self-limited course of HCV 
infection were able to inhibit HCV replication to a greater extent than NK cells from 
patients who developed chronic course of infection. Functional analysis showed a pos-
itive correlation between NK cell anti-HCV activity and IFN-g secretion whereas no 
such observations were made with respect to NK cell degranulation. Blocking of IFN-g 
suggested a key role for NK cell-mediated inhibition of HCV replication. In line with 
this, NK cells from patients with a self-limited course produced significantly more IFN-
g than NK cells from patients with a chronic course. Further we found that high expres-
sion of NKp46 and NKG2D defines NK cell subpopulations which display a robust anti-
HCV activity and are able to modulate outcomes of acute HCV infection favoring spon-
taneous clearance via IFN-g secretion. Blocking of these receptors significantly re-
duced antiviral NK cell activity. Regarding CD3(+)CD56(+) NK-like T cells from healthy 
individuals, we found that stimulation with IL-12/IL-15 significantly increased efficacy 
to inhibit HCV replication in vitro via IFN-g secretion. In line with our previous observa-
tions from the NK cell analysis, blocking of IFN-g decreased anti-HCV activity of NK-
like T cells. However, no correlation was found between degranulation and inhibition 
of HCV replication. Instead, we found NK-like T cells from HIV+ mono infected patients 
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to display a significantly impaired IFN-g production and consequently to show signifi-
cantly worse capacity to inhibit HCV replication than healthy controls.   
In conclusion, our results demonstrate a critical role of NK cell subpopulations and their 
capacity to modulate IFN-g production as a key factor for a robust anti-HCV response. 
We could show that NK cell-mediated IFN-g production was associated with spontane-
ous clearance of acute hepatitis C in HIV+ patients. Despite the fact that NK-like T cells 
also possess the ability to inhibit HCV replication in an IFN-g-dependent manner, their 
capacity to produce IFN-g seems to be negatively affected by HIV infection, so that 
they can contribute only insignificantly to the clearance of hepatitis C virus in HIV in-
fected patients. 
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1 Introduction 
1.1 Hepatitis C Virus (HCV) 
Hepatitis C represents an inflammation of the liver caused by the hepatitis C virus 
(HCV). This parenterally acquired disease, especially through blood transfusion, was 
initially described as post-transfusion hepatitis, or non-A-non-B hepatitis [1]. In 1989 
the group of Choo et al. succeeded in isolating viral RNA [2] and the subsequent char-
acterization of HCV as single-stranded RNA virus with positive polarity (5’ -> 3’) 
(ss(+)RNA). Next HCV was assigned to the family of Flaviviridae. Until now, seven 
different genotypes have been determined [3]. Worldwide around 71 Mio people (1%) 
of the global population, are chronically infected with HCV. WHO estimates that there 
were approximately 1.75 million new infections in 2015 and around 400000 infected 
individuals die from HCV every year [4]. Until now, there is no HCV vaccination avail-
able.  
1.1.1 Transmission 
The transmission of the HCV occurs via blood-blood contact. Thus, patients who fre-
quently received blood transfusions or blood products (hemophilia patients) had the 
biggest risk of infection until the identification of the hepatitis C virus as pathogen caus-
ing non-A-non-B hepatitis [5]. Today, people with drug addiction are the most vulnera-
ble risk group. The infection occurs from contaminated drug paraphernalia [6]. The risk 
of a sexual transmission is generally perceived as low. Nevertheless, over the last ten 
years a significant increase of new infections can be observed among homosexual 
men. Besides other causes, this is attributed to an increased risk of infection due to 
traumatic sexual practices, which can lead to mucous membrane injuries [7]. 
1.1.2 Clinical course 
Since the infection is asymptomatic in most cases, it often remains undiscovered at 
first. After an incubation period of approx. 8 (2-26) weeks a temporary increase of 
transaminases occurs. Only a small proportion of patients (10-20%) shows a strong 
increase of liver enzymes or icterus. During this time, around one third of patients suf-
fers from flu-like symptoms. The chronic infection, on the other hand, is asymptomatic, 
except for a general fatigue. Only in 20-30% of patients the virus can be eliminated by 
the endogenous immune response during the acute phase, which usually describes 
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the first six months of the infection. However, in most cases the acute hepatitis devel-
ops into a chronic hepatitis C (CHC). Over the clinical course, the CHC can develop 
from a simple infection of the liver (mild hepatitis) to a cirrhosis and even to a hepato-
cellular carcinoma. Around 20% of chronically infected HCV patients develop a liver 
cirrhosis within 20 years. When cirrhosis is established, the development rate of the 
hepatocellular carcinoma is around 1-5 % per year [3].            
1.2 Human Immunodeficiency-Virus (HIV) 
HIV is a RNA virus with positive polarity (5’ -> 3’) (ss(+)RNA) and belongs to the Family 
of Retroviridae. Until today, two different HIV types are known. HIV-Type1 was discov-
ered in 1983 [8] and HIV-Type 2 in 1986. HIV-Type 1 is distinguished in four subgroups 
(M, N, O and P), which are again classified in several subtypes. To date, around 60 
million of HIV-positive people are infected with HIV-Type1 of the subgroup M, which is 
also responsible for almost all AIDS cases [9]. In 2016, around 36.7 million people 
around the world lived with an HIV infection and 1.8 million people became newly in-
fected [10].     
1.2.1 Transmission 
The transmission via sexual contact is the dominant path of infection, followed by use 
of contaminated drug paraphernalia. The perinatal transmission from a mother to a 
child is also possible. On the other hand, infections from blood transfusions or organ 
transplantations are very rare since the introduction of HIV tests. The risk of infection 
correlates with the present amount of virus in the blood or sperm and in the vaginal 
secretion, since the highest virus concentrations are measurable here [11]. The HIV 
enters the target cell via the CD4 receptor, which is expressed mostly by T cells, but 
also by monocytes, macrophages and dendritic cells (DC).    
1.2.2 Clinical course 
After successful entry into the cell, the virus begins to replicate itself, which leads to 
the reproduction and release of new virus particles, which infect the CD4(+) cells. The 
CD4(+) T (T helper) cells are the most affected celltype and their number decreases 
with increasing viral load. In most cases the infection is asymptomatic at first, although 
in some patients an acute, retroviral syndrome with flu-like symptoms and swelling of 
lymph nodes can occur. This phase usually lasts for up to four weeks. After this phase, 
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the number of CD4(+)T cells increases again and the viral load decreases. The im-
mune system stabilizes temporarily through the initiation of a longtime immune re-
sponse. Without a highly active antiretroviral therapy (HAART), over the course of ten 
years the clinical course is usually a constant decrease of CD4(+)T cells, an increase 
of the viral load and the potential occurrence of opportunistic diseases until finally the 
stage acquired immune deficiency syndrome (AIDS) is reached [11].       
1.3 HIV/HCV co-infection 
Due to similar transmission pathways, a relevant proportion of HIV patients show a co-
infection with the hepatitis C virus. In Germany, around 15%, in other European coun-
tries and the USA around 33% of all HIV(+) patients are HCV co-infected [11]. In sev-
eral studies it could be verified that co-infection with HIV has a negative impact on the 
course of the hepatitis C infection due to the concomitant compromise of the immune 
system. Therefore, on average co-infected patients have higher HCV viral loads than 
people with HCV mono-infection. Furthermore, HIV/HCV co-infection is associated 
with a faster progression towards liver fibrosis and liver cirrhosis which leads to liver 
failure and increased mortality [12], [13]. To date, liver failure is the most frequent 
cause of death in HIV/HCV patients [14]. The treatment is also more complex in co-
infected patients, compared to people with a mono-infection. For example, an increase 
of hepatotoxicity of antiretroviral substances has been observed for HCV infections, 
where up to 10% of treated patients did not tolerate the therapy and had to change the 
medication [9].   
1.4 Natural Killer cells (NK cells) 
NK cells, a sub-population of lymphocytes, are an integral element of the innate im-
mune system. They are characterized by the presence of CD56 (N-CAM) and the ab-
sence of the CD3 receptor. Around 90% of circulating NK cells (CD3-CD56dimCD16+) 
express low amounts of CD56 on their surface. These cells express CD16 (FcgRIII), 
the receptor of the IgG Fc fragment and exercise strong cytotoxic effects. A second 
sub-population expresses higher amounts of CD56 but no CD16 (CD3-
CD56brightCD16-). Immune regulatory properties such as a distinct IFN-g production, 
are associated with the CD56bright subtype [15]. In healthy individuals, they represent 
5-15% of the total peripheral mononuclear blood cells (PBMC) and up to 45% of the 
intrahepatic lymphocytes [16]–[18]. A relevant function of NK cells is the destruction of 
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transformed or (intracellularly) infected cells, infected from either viruses or bacteria. 
In contrast to T cells, NK cells are able to trigger an immune response without prior 
‘priming’. The activity of NK cells is regulated by NK cell receptors (NKR), which can 
be distinguished in activating or inhibiting NKR. The natural cytotoxicity receptors 
(NCR), among others, as well as some members of the NKG2 family belong to the 
activating receptors [19].     
1.4.1 Natural cytotoxicity receptors  
The activation of natural killer cells is primarily mediated via the natural cytotoxicity 
receptors NKp30, NKp44 and NKp46 [20], which belong to the Ig superfamily. NKp30 
and NKp46 are expressed on both, resting as well as activated NK cells. NKp44 on 
the other hand, can be found only on cytokine-activated NK cells. NKp46 binds N-
acetylneuramine –binding glycoproteins e.g. hemagglutinin, as well as hemagglutinin 
neuraminidase from influenza and parainfluenza viruses. The natural ligands for 
NKp30 and NKp44 are not yet known [21], [22].     
1.4.2 CD94/NKG2-Receptors 
Type II lectin-like, integral membrane glycoproteins give rise to the so-called 
CD94/NKG2 receptors. On the cell surface NKG2 proteins form heterodimers with 
CD94, which is the invariant Type II, lectin-like polypeptide. CD94 itself cannot transmit 
any signals, since it does not have a cytoplasmic tail, which is essential for the surface 
expression of NKG2 receptors. While some of the NKG2 receptors have an activating 
function (NKG2C, H and E), others have inhibiting properties (NKG2A and B). The 
ligand for CD94/NKG2A and CD94/NKG2C is the non-classic MHC I-molecule HLA-E 
[23]–[25].     
1.4.3 NKG2D 
NKG2D is the only known member of the NKG2 family that is not expressed via cova-
lent binding to CD94. Its cognate ligands are MICA, MICB and ULBPs, among others, 
which in terms of structure resemble MHC-I-like proteins. After binding to its ligand, the 
NKG2D receptor transmits activating signals, which increase the cytotoxicity of NK 
cells and also trigger the production of IFN-g [26]–[28]. 
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1.5 NK cells in HCV mono-infection 
As part of the innate immune system NK cells play an important role in the defense 
against pathogens, since they are able to inhibit the viral replication in the early phase 
of the virus infection as well as to induce a strong adaptive immune response. Regard-
ing hepatitis C, epidemiologic data as well as in vitro experiments verify, that NK cells 
are activated and potentially transmit protection against a HCV infection and can pos-
itively affect the natural course of the infection [29]–[32]. It could be demonstrated in 
vitro, that HCV replication can be inhibited via an IFN-g dependent mechanism by cy-
tokine-activated NK cells [33], [34]. Recently published studies in HCV(+)/ HIV(-) pa-
tients show, that an activation of the NK cell population occurs during the acute phase 
of the HCV infection, independent of the further course of the infection (self-limiting vs 
chronic). The questions to which degree and via which mechanisms NK cells regulate 
the immune elimination of the virus could not be finally resolved during the research. 
However, Alter et al. found that the expression of NKp46 and NKG2D significantly dif-
fered between NK cells of patients with self-limiting hepatitis C and patients with a 
chronic course of infection. This indicates a great importance of NKp46(+) and 
NKG2D(+) NK cells within the context of the acute hepatitis C [29], [35], [36]. 
1.6 NK-like T cells and HCV  
CD3(+)CD56(+) NK-like T cells are another subpopulation of innate lymphocytes which 
share several characteristics with NK cells. This includes their large granular lympho-
cyte morphology, their potency to lyse NK-sensitive target cells as well as their 
functional regulation, which is mediated by classic NK cell receptors [37]. 
CD3(+)CD56(+) NK-like T cells represent approximately 5%–15% of the peripheral T 
cell pool and up to 50% of T cells in the liver, which must be considered as the main 
site of HCV replication [38]. CD3(+)CD56(+) NK-like T cells are co-expressing NK cell 
markers, capable of leading to either suppression or stimulation of immune responses 
[37]. Because of the fact that CD3(+)CD56(+) NK-like T cells can mediate both MHC-
restricted and MHC-unrestricted cytotoxicity as well as cytokine production, they show 
properties of both T and NK cells [39], [40]. Phenotypic and functional alterations of 
CD3(+)CD56(+) NK-like T cells have been revealed to be associated with the outcome 
of acute hepatitis C in HIV-positive patients [41], indicating that this lymphocyte subset 
might influence the immunopathogenesis of HCV infection. Furthermore the role of 
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CD3(+)CD56(+) NK-like T cells in hepatitis C manifests itself by the detection that in 
the livers of patients with chronic HCV infection the numbers of CD3(+)CD56(+) NK-
like T cells are notably decreased. This condition may be related to an increased sus-
ceptibility to develop hepatocellular carcinoma [42]. Anyway, it has been shown that 
exposure to HCV is associated with both increased activation and degranulation of 
NKT cells [43], [44]. However, it is still unclear whether CD3(+)CD56(+) NK-like T cells 
exert direct activity against HCV. Additionally, it has not been investigated yet if HIV 
coinfection affects anti-HCV activity of CD3(+)CD56(+) NK-like T cells. Concerning 
this, it is necessary to consider that HIV infection has been revealed to be associated 
with a decrease in CD3(+)CD56(+) NK-like T cells number and morphological and 
functional changes of CD3(+)CD56(+) NK-like T cells [45], [46]. 
1.7 Aim of the thesis  
This present work focuses on the exploration and research of the role of natural killer 
cells (NK cells), as well as natural killer-like T cells (NK-like T cells) during the acute 
Hepatitis C virus infection in HIV(+) patients. The experiments emphasize both, the 
intracellular, as well as the extracellular characterization of NK and NK-like T cells, and 
their functions. Here, the analysis addressed the expression of the activating and in-
hibiting receptors as well as the maturation markers on NK and NK-like T cells. Further, 
the cytotoxicity (CD107a), antiviral activity (Luciferase) as well as cytokine profile (IFN-
g) of NK and NK-like T cells, were investigated. These investigations help to under-
stand which mechanisms are involved in the spontaneous clearance of hepatitis C in 
its early stage in HIV+ patients. 
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2 Materials 
2.1 Devices 
Laminar flow cabinet Microflow GmbH, Germany 
Flow cytometer FACSCanto II BD, Germany 
CO2 incubator Forma Scientific, Germany 
Inverted microscope (DM/LS) Leica Microsystems, Germany 
Cooling centrifuge Beckman Coulter, Germany 
Benchtop centrifuge MIKRO 22R Hettich, Germany 
Luminescence reader  Wallac, USA 
OctoMACS separator Miltenyi, Germany 
Elisa reader Tecan, Switzerland 
Shaker VWR, Germany 
Vortex Scientific Idustries, USA 
Neubauer chamber Brand, Germany 
2.2 Disposable materials 
Polypropylene reaction tube (1.5µl) Eppendorf, Germany  
Polypropylene tube (14, 50 µl) Greiner Bio-One, Germany 
Pipettes (5, 10, 25 ml) Greiner Bio-One, Germany 
Pasteur pipettes Brand, Germany 
Pipettes (10, 100, 200, 1000ml) Eppendorf, Germany 
Disposable gloves Ansell, Belgium 
Microscope slides Menzel, Germany 
Coverslips Menzel, Germany 
S-Monovette for heparin whole blood Sarstedt, Germany 
Cell culture plates (96-, 48-, 24- well) Greiner Bio-One, Germany 
Cell culture flasks (25, 75, 175 cm2) Greiner Bio-One, Germany 
Polystyrene FACS tubes Sarstedt, Germany 
MACS columns Miltenyi, Germany 
96-well white solid plate Corning Incorporated, USA 
 
2.3 Media, Buffers and Kits 
RPMI 1640 Medium with L-Glutamin PAA Laboratories, Austria 
DMEM Medium with L-Glutamin PAA Laboratories, Austria 
Fetal calf serum (FCS) Biochrom, Germany 
Penicillin/Strepromycin PAA Laboratories, Austria 
Phosphate-buffered saline (PBS) Pharmacy Univ. Hospital Bonn, Germany 
Ampuwa (sterile Aqua dest.) Fresenius, Germany 
Ethanol absolute Merck, Germany 
Accutase PAA Laboratories, Austria 
Dimethyl sulfoxide (DMSO) Merck, Germany 
Ficoll (Lymphocyte separation Medium) PAA Laboratories, Austria 
Cytofix/CyropermTM BD, Germany 
CellFIXTM BD, Germany 
Trypan blue Merck, Germany 
Brefeldin-A (BFA) Biolegend, USA 
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Golgi-Stopp BD, Heidelberg 
Steady Glo Promega, USA 
Recombinant human IL-2 R&D Systems 
Recombinant human IL-12 R&D Systems 
Recombinant human IL-15 R&D Systems 
96-well human IFN-g ELISA kit Diaclone, USA 
NK Cell Isolation Kit, human Miltenyi, Germany 
CD3+CD56+ NKT Cell Isolation Kit, human Miltenyi, Germany 
 
2.4 Antibodies 
 
Antibody Clone Isotype Manufacturer 
Anti-CD3-APC-Cy7 UCHT1 Mouse IgG1 k Biolegend 
Anti-CD3-PerCP SK7 Mouse IgG1 k Biolegend 
Anti-CD27-PE O323 Mouse IgG1 k Biolegend 
Anti-CD56-APC HCD56 Mouse IgG1 k Biolegend 
Anti-CD57-APC HCD57 Mouse IgM k Biolegend 
Anti-CD62L-FITC DREG-56 Mouse IgG1 k Biolegend 
Anti-CD69-PE 298614 Mouse IgG2A R&D Systems 
Anti-CD107a-PE H4A3 Mouse IgG1 k BD Pharmingen 
Anti-CD127-FITC A019D5 Mouse IgG1 k Biolegend 
Anti-CD161-FITC HP-3G10 Mouse IgG1 k Biolegend 
Anti-CD158e-FITC DX9 Mouse IgG1 k Biolegend 
Anti-IgG1-PE MOPC-21 Mouse IgG1 k BDPharmingen 
Anti-IgG1-PE RMG1-1 Rat IgG1 Biolegend 
Anti-IgG1-FITC RMG1-1 Rat IgG1 Biolegend 
Anti-IgG1-PE 97924 Mouse IgG1 R&D Systems 
LEAF Anti-IgG1 MOPC-21 Mouse IgG1 Biolegend 
Anti-NKG2A-PE 131411 Mouse IgG2A R&D Systems 
Anti-NKG2C-PE 134591 Mouse IgG1  R&D Systems 
Anti-NKG2D-PE 149810 Mouse IgG1  R&D Systems 
Anti-NKp46-FITC 9E2 Mouse IgG1 Biolegend 
Anti-IFN-g-PE 25723 Mouse IgG2B R&D Systems 
Anti-NKG2D (block) 149810 Mouse IgG1 R&D Systems 
Anti-NKp46 (block) No indication Goat IgG R&D Systems 
Anti-IFN-g (block) NIB42 Mouse IgG1 Biolegend 
LEAF Anti-IFN-g (ELISA) NIB42 Mouse IgG1 k Biolegend 
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2.5 Media composition 
2.5.1 Lymphocyte Medium 
RPMI 1640 Medium with L-Glutamine 
10% FCS 
1% Penicillin/Streptomycin 
2.5.2 Huh7-HCVreplicon cells Medium 
DMEM Medium with L-Glutamine 
10% FCS 
1% Penicillin/Streptomycin 
2% G418 
1% NEA 
0.06% Blasticidin S 
2.5.3 Cryoprotectant Medium 
RPMI 1640 Medium with L-Glutamine 
10% FCS 
10% DMSO 
2.6 Buffer 
2.6.1 MACS-Buffer 
PBS 
0.5% BSA 
2mM EDTA 
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3 Methods 
3.1 Patients 
Blood samples were collected from HIV-positive patients with acute hepatitis C and 
different outcomes of the HCV infection. For the NK cell project, 27 patients with acute 
hepatitis C and different outcomes of HCV infection were analyzed (Table 1). For the 
NK-like T cell project, 36 patients with acute hepatitis C and different outcomes of HCV 
infection were analyzed (Table 2). As controls, 12 patients with HIV/HCV chronic in-
fection, 8 HIV mono-infected patients as well as 12 healthy individuals (HIV-/HCV-) 
were studied. The samples were collected during the acute hepatitis C diagnosis, from 
the HIV outpatient clinic from the Bonn University hospital as well as from the Praxis 
am Ebertplatz, Cologne. For the NK cell study, all HIV-positive patients were HIV RNA-
negative under effective HAART. In the NKT cell study, 9 out of 36 aHCV/HIV-positive 
co-infected patients had a HIV viremia <27.000 copies/ml. Informed consent was ob-
tained from all patients. The study had been approved by the local ethics committee of 
the University of Bonn (Bonn, Germany).
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healthy controls 
Number 12 
Male sex a) 7 (58%) 
Age (years) c) 30.4 (21-54) 
Risk Factors 
MSM a),b) - 
Others/Unknown a) - 
Clinical data 
ALT U/L c)   n.a. d) 
AST U/L c)   n.a. d) 
HIV-Status 
HIV RNA negative (under HAART)   a) - 
CD4 cells /µl  c)   n.a. d) 
CD8 cells /µl  c)   n.a. d) 
HCV-Status 
HCV Load  (x 10 6  IU/mL) c) - 
HCV-Genotypes: 
Genotype 1 a) - 
Genotype 2 a) - 
Genotype 3 a) - 
Genotype 4 a) - 
Undetermined Genotype a) 
 acute -> self-limited 
10 
10 (100%) 
39.1 (31-46) 
9 (90%) 
1 (10%) 
742 (23 - 3208) 
493 (16 - 1638) 
10 (100%) 
647 (358 - 873) 
1205 (407 - 1794) 
15.9 (<0.1 -69) 
8 (80%) 
0 (0 %) 
0 (0 %) 
0 (0 %) 
2 (20%) 
 acute -> chronic 
17 
17 (100%) 
41.6 (34-49) 
16 (94%) 
1 (6%) 
651 (26 - 2262) 
348 (24 - 2006) 
17 (100%) 
698 (300 - 1377) 
1118 (220 - 2775) 
10.7 (<0.1 - 69) 
12 (71%) 
0 (0 %) 
0 (0 %) 
5 (29 %) 
0 (0 %) 
HIV(+) / cHCV 
12 
11 (92%) 
47.8 (38-58) 
6 (50%) 
6 (50%) 
70 (4 - 181) 
49 (20 - 102) 
12 (100%) 
620 (182 - 1151) 
631 (254 - 2249) 
4.9 (0.8 - 26) 
10 (83%) 
0 (0 %) 
0 (0 %) 
2 (17 %) 
0 (0 %) - 
a) number of cases (number/total in %) 
b) MSM; men who have sex with men 
c) mean (range) 
d) na - not analyzed 
HIV(+) / aHCV 
Table 1. Patient Characteristics 
HIV(+) / HCV(-) 
8 
6 (75%) 
51 (35-66) 
6 (75%) 
2 (25%) 
26 (16 - 40) 
20 (16 - 24) 
8 (100%) 
737 (421 - 1199) 
1128 (366 - 1940) 
- 
- 
- 
-  
- 
- 
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healthy controls 
Number 12 
Male sex a) 7 (58%) 
Age (years) c) 30.4 (21-54) 
Risk Factors 
MSM a),b) - 
Others/Unknown a) - 
Clinical data 
ALT U/L c)   n.a. d) 
AST U/L c)   n.a. d) 
HIV-Status 
HIV RNA negative (under HAART)   a) - 
CD4 cells /µl  c)   n.a. d) 
CD8 cells /µl  c)   n.a. d) 
HCV-Status 
HCV Load  (x 10 6  IU/mL) c) - 
HCV-Genotypes: 
Genotype 1 a) - 
Genotype 2 a) - 
Genotype 3 a) - 
Genotype 4 a) - 
Undetermined Genotype a) 
 acute -> self-limited 
13 
13 (100%) 
39 (31-50) 
11 (85%) 
2 (15%) 
721 (23 - 3208) 
459 (16 - 1638) 
11 (85%) 
670 (358 - 904) 
1221 (407 - 1794) 
14.7 (<0.1 -69) 
8 (62%) 
0 (0 %) 
0 (0 %) 
0 (0 %) 
5 (38%) 
 acute -> chronic 
23 
23 (100%) 
41.22 (27-49) 
21 (91%) 
2 (9%) 
629 (21 - 3644) 
345 (24 - 2006) 
16 (70%) 
627 (300 - 1377) 
1105 (220 - 2775) 
11.2 (<0.1 - 69) 
15 (65%) 
0 (0 %) 
0 (0 %) 
7 (31 %) 
1 (4 %) 
HIV(+) / cHCV 
12 
11 (92%) 
47.8 (38-58) 
6 (50%) 
6 (50%) 
70 (4 - 181) 
49 (20 - 102) 
12 (100%) 
620 (182 - 1151) 
631 (254 - 2249) 
4.9 (0.8 - 26) 
10 (83%) 
0 (0 %) 
0 (0 %) 
2 (17 %) 
0 (0 %) - 
a) number of cases (number/total in %) 
b) MSM; men who have sex with men 
c) mean (range) 
d) na - not analyzed 
HIV(+) / aHCV 
Table 2. Patient Characteristics 
HIV(+) / HCV(-) 
 
8 
6 (75%) 
51 (35-66) 
6 (75%) 
2 (25%) 
26 (16 - 40) 
20 (16 - 24) 
8 (100%) 
737 (421 - 1199) 
1128 (366 - 1940) 
- 
- 
- 
-  
- 
- 
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3.2 Isolation of peripheral blood mononuclear cells (PBMC) 
PBMCs were separated from heparinized whole blood by the method developed by 
Böyum [47]. For this purpose the whole blood is applied to a Ficoll density gradient. 
Ficoll is a sugar polymer with a density of 1.077 g/cm3. Due to their specific density, 
monocytes and lymphocytes remain as a milky cloud above the gradient, while eryth-
rocyte granulocyte agglomerates pass through the polymer and are pelleted in the 
sediment. 
 
Procedure: 
- Place 15 ml of Ficoll (D = 1.077) in a sterile 50 ml Falcon tube  
- Carefully overlay the Ficoll with the heparinized blood  
- Centrifuge 20 min, 900 * g, RT, without brake 
- Remove milky lymphocyte ring, into a new 14 ml Falcon Tube  
- Wash with PBS  
- Centrifuge 10 min, 450 * g, RT  
- Remove supernatant   
- Resuspend the pellet in 14 ml of PBS  
- Centrifuge 10 min, 300 * g, RT  
- Remove supernatant  
- Resuspend the pellet in cryoprotectant medium 
3.3 Cell count 
Cell count is carried out according to the method developed by Neubauer. Ten µl of 
trypan blue cell suspension (1:1) are added to a counting chamber, which is closed 
with a cover glass. Trypan blue is a vital dye in order to distinguish dead and alive 
cells. If the cells are dead and their membrane is no longer intact, the dye penetrates 
them and stains the cytoplasm of the cell blue. Only living cells are counted during the 
cell count. The counting area consists of four large squares and each one contains 16 
small squares. The number of cells is calculated according to the following formula:  
 
Number of cells in 16 squares x dilution factor 2 x chamber factor 10 x total 
volume of the cell suspension in µl 
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3.4 Flow cytometry  
Flow cytometry allows for the simultaneous determination of different cell properties, 
such as size, granularity and the expression of extra- and intracellular molecules. The 
flow cytometry is based on the following principle: the examined cells are taken up by 
a carrier liquid and individually pass a laser beam. When light hits the cell, it is scattered 
and re-emitted. The forward light measured here (Forward Scatter/ FSC) allows for a 
statement on the size and the sideways light (Sideward Scatter / SSC) gives infor-
mation on the granularity of the cells.     
For fluorescence-activated cell sorting (FACS) the following antibodies were used: 
anti-CD3-PerCP, anti-CD3-APC-Cy7 anti-CD56-APC, anti-CD27-PE, anti-CD57-FITC, 
anti-CD62L-FITC, anti-CD127-FITC, anti-CD158e-FITC, anti-CD161-FITC and anti-
NKp46-FITC (Biolegend, Fell, Germany); anti-CD69-PE, anti-NKG2A-PE, anti-
NKG2C-PE, anti-NKG2D-PE and anti-IFN-g-PE (R&D Systems, Wiesbaden-Norden-
stadt, Germany); anti-CD107a-PE (BD Biosciences, Heidelberg, Germany) and 
eFluor670 (eBioscience, Frankfurt, Germany). The samples were analyzed on a 
FACSCanto II flow cytometer using the  CellQuest Pro (BD Biosciences) and Flowjo 
7.5 software packages (TreeStar Inc., Ashland, OR). 
3.5 Phenotyping of NK and NK-like T cells 
In order to determine the NK and NK-like T cell phenotype, the cells are stained with 
several specific antibodies. The dye helps to identify the percentage as well as the 
relative fluorescence intensity (RFI) of the surface expression of these antigens. NK 
cells are defined as CD3-/CD56+ cells and the NKT cells as CD3+/CD56+ cells. All 
cells located above the isotype control are considered to be positive. The RFI is calcu-
lated by the following formula:  
 
RFI= (median observation – median isotype control) / median isotype control 
 
Procedure:  
- Thaw cells in water bath 
- Wash with PBS 
- Centrifuge for 10min, 300*g, RT 
- Discard supernatant  
- Re-suspend in RPMI 10% FCS 1% P/S 
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- Determine cell number (Neubauer chamber) 
- Transfer 200,000 cells each into 3 FACS tubes 
- Surface dye with  
      for all batches  5 µl anti-CD56-APC 
1 µl anti-CD16-PerCP   
5 µl anti-CD3-APC-Cy7      
 1 µl DAPI (20 sec. before measurement) 
tube allocation: 
 1: 5 µl anti-CD161-FITC, 5 µl anti-NKG2C-PE 
 2: 5 µl anti-CD62L-FITC, 5 µl anti-NKG2D-PE 
 3: 5 µl anti-CD158e-FITC 
 4: 5 µl anti-NKp46-FITC, 5 µl anti-NKG2A-PE 
 5: 5 µl anti-CD57-FITC, 5 µl anti-CD69-PE 
 6: 5 µl anti-CD127-FITC, 5 µl anti-CD27-PE 
 7: 5 µl anti-IgG1-FITC, 5 µl anti-IgG1-PE 
- incubate in the dark for 20 mins  
- wash with PBS 
- centrifuge for 10 min, 300*g, RT 
- take up cells with cellfix 
- measure immediately or store in the dark at 4°C for up to 24 h and then measure 
3.6 NK cell and NKT cell separation 
Natural killer or natural killer-like T cells were immunomagnetically separated from total 
peripheral blood mononuclear cells (PBMC) using MACS cell separation technology, 
and applying the manufacturer`s recommendations (Miltenyi Biotec, Bergisch Glad-
bach, Germany).  The NK cells separation was done by a negative selection. This 
means that all non-NK cells, i.e. B cells, T cells, dendritic cells, granulocytes, mono-
cytes and erythroid cells were labeled with a cocktail of biotin-coupled antibodies 
against specific surface molecules. Then a secondary antibody which is conjugated on 
magnetic particles binds the biotin group of the primary antibody (anti-biotin). Following 
this procedure labeled cells are then transferred to MACS columns which are placed 
in a magnetic field. All labeled cells with magnetic beads are retained in the column, 
while the unlabeled cells pass through the magnetic field. The NK-like T cells separa-
tion was provided by a positive selection in two steps. First NK cells were labeled with 
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a cocktail of biotin conjugated primary antibodies against surface molecules and sec-
ondary antibodies with magnetic anti-biotin microbeads. All labeled cells were then 
depleted by separation through a column placed in a magnetic field. In the second 
step, CD56 microbeads were used to positively isolate CD3+CD56+ NKT cells from 
the pre-enriched NKT cell population from the first step. The purity of NK and NKT cells 
was >95%. Purified NK or NK-like T cells were cultivated in RPMI1640 medium sup-
plemented with 10% FCS and 1% penicillin/streptomycin at 37°C and 5% CO2. 
 
Procedure for NK cell separation: 
- Resuspend 107 PBMCs in 40 μl MACS buffer 
- Add 10 μl of the NK cell biotin antibody cocktail 
- Incubate for 10 min at 4 ° C 
- Add 30 μl of MACS buffer and resuspend 
- Add 20 μl of the NK cell microbead cocktail 
- Incubate for 15 min at 4 ° C 
- Wash with MACS buffer 
- Centrifuge 10 min, 300 * g, 4 ° C 
- Resuspend in 500 μl MACS buffer 
- Prepare MACS columns by rinsing with 500 μl MACS buffer 
- Add the suspension to the columns and let it pass completely 
- Wash columns three times with 500 μl MACS buffer each time 
- Wash with PBS 
- Centrifuge 10 min, 300 * g, 4 ° C  
- Resuspend in 1 ml of RPMI 10% FCS, 1% P / S  
 
Procedure for NKT cell separation: 
- Resuspend 108 PBMCs in 40 μl MACS buffer 
- Add 100 μl of the CD3+CD56+ NKT cell biotin antibody cocktail 
- Incubate for 10 min at 4 ° C 
- Wash with MACS buffer 
- Centrifuge 10 min, 300 * g, 4 ° C 
- Resuspend in 400 μl MACS buffer 
- Add 100 μl of anti-biotin microbeads 
- Incubate for 15 min at 4 ° C 
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- Wash with MACS buffer 
- Centrifuge 10 min, 300 * g, 4 ° C 
- Resuspend in 500 μl MACS buffer 
- Prepare LD MACS columns by rinsing with 2 ml MACS buffer 
- Add the suspension to the columns and let it pass completely 
- Wash columns two times with 2 ml MACS buffer each time 
- Collect total effluent (pre-enriched NKT cell fraction)  
- Centrifuge 10 min, 300 * g, 4 ° C 
- Resuspend in 400 μl MACS buffer 
- Add 100 μl of the NK cell microbead cocktail 
- Incubate for 15 min at 4 ° C 
- Wash with MACS buffer 
- Centrifuge 10 min, 300 * g, 4 ° C 
- Resuspend in 500 μl MACS buffer 
- Prepare MS MACS columns by rinsing with 500 μl MACS buffer 
- Add the suspension to the columns and let it pass completely 
- Wash columns three times with 500 μl MACS buffer each time 
- Place column on a collection tube 
- Add 1 ml of MACS buffer onto the columns and immediately flush out the fraction 
with magnetically labeled CD3+CD56+ NKT cells  
- Wash with PBS and resuspend in 1 ml of RPMI 10% FCS, 1% P / S 
3.7 Interferon-gamma (IFN-g) Assay (Flow cytometry) 
A part of the immune response is the production of chemical transmitter substances, 
the cytokines. An important cytokine, which has both, antiviral as well as immune stim-
ulating properties, is IFN-g. The number of IFN-g-positive NK and NK-like T cells is 
determined by flow cytometry in this work. For this purpose, the cells are treated with 
Brefeldin A (BFA), a Golgi inhibitor. This results in an accumulation of IFN-g in the cell. 
Afterwards, the cells are made permeable and stained with a specific IFN-g antibody.         
Cells were cultivated for 18 hours in the presence or absence of recombinant human 
interleukin (rhIL)-12 (1 ng/mL) and rhIL-15 (10 ng/mL).  For some experiments IL-2-
prestimulated NK cells were co-cultivated for 5 hours with Huh7-HCVreplicon cells at 
1:1 effector:target (E:T) ratio at 37°C. Then, brefeldin A (10 mikrog/mL) was added for 
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another 4 hours or 1 hour of co-cultivation respectively, followed by intracellular stain-
ing with anti-IFN-g mAb and FACS analyses. 
 
Procedure: 
- plate 1 x 105 cells in 96-well plates twice 
-stimulate cells with 1ng/ml IL-12 & 10ng/ml IL-15 for 18 h 
- after 18 h, add Brefeldin A   
- 5 h incubation at 37°C, 5% CO2 
- resuspend cells thoroughly and transfer cell suspensions to FACS tubes 
- Surface staining in FACS tubes with 5 μl anti-CD56-APC and 1 μl anti-CD3-PerCP  
- incubate in the dark for 20 min. at RT  
- Bring Facs tubes to a total volume of 3 ml by adding PBS and spin down for 10   
min., at 300*g 
- discard supernatant and resuspend cells in 250 µl Cytofix/Cytoperm 
- incubate in the dark for 20 min. at 4°C  
- wash cells with 500 µl Perm/Wash 
- Centrifuge for 10 min.,300*g, at 4 °C 
- Wash cell suspension with 500 µl Perm/Wash 
- Spin down for 10 min., 300*g, at 4 °C 
- Discard supernatant and resuspend pellet with Perm/Wash 
- Add 5 µl IFN-g PE Ab. 
- Incubate cells in the dark at 4 °C 
- Wash with 1 ml Perm/Wash 
- Centrifuge for 10 min., 300*g, 4 °C 
- Discard supernatant and resuspend cell pellet with 150 µl PBS 
- Immediately analyse cells or store cells in the dark, at 4 °C for 24 h max.  
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3.8 IFN-g Enzyme-Linked Immunosorbent Assay  
Enzyme-linked immunosorbent assay (ELISA) is a microtiter plate-based assay involv-
ing antibodies in the detection and quantification of proteins. The plate surface is 
coated with a high specificity anti-IFN-g capture antibody. Samples including antigen 
are then applied to the wells and the antigen is binding to the capture antibody. Bioti-
nylated anti-IFN-g antibody is given to the wells, which after addition of its substrate 
(enzyme- conjugated streptavidin) produces a detectable signal.  
After co-incubation of Huh7-HCVreplicon cells with sorted NK or NK-like T cells, over-
night supernatants were collected and IFN-g concentrations were analyzed by enzyme-
linked immunosorbent assay (ELISA), following the manufacturer’s instructions. 
 
Procedure: 
- Prepare standard curve 
- Add 100μl of each sample, control and zero control (Standard diluent) 
- Add 50μl of diluted biotinylated anti-IFN-g  
- cover and incubate at room temperature (18 to 25°C) for 2 hours 
- Washing steps:  
a) Aspirate the liquid from each well 
b) Dispense 0.3 ml of 1x washing solution into each well 
c) Aspirate the contents of each well 
d) Repeat step b and c two more times 
- Add 100μl of streptavidin-HRP solution 
- cover and incubate at room temperature (18 to 25°C) for 30 min 
a) Aspirate the liquid from each well 
b) Dispense 0.3 ml of 1x washing solution into each well 
c) Aspirate the contents of each well 
d) Repeat step b and c two more times 
- Add 100μl of ready-to-use TMB substrate solution 
- Incubate in the dark for 12-15 minutes at room temperature 
- Add 100μl of H2SO4: “Stop Reagent” 
- Read the absorbance value immediately on a spectrophotometer 
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3.9 CD107a Degranulation and Killing Assay  
CD107a or LAMP-1 (lysosome-associated membrane protein-1) is a functional marker 
for NK cell activity [48].  CD107a can be found on the inner membrane side of granules 
in resting NK cells. After activation of the NK cells, the granules fuse with the plasma 
membrane (exocytosis), and their contents are released into the extracellular space. 
The CD107a protein is now on the NK cell surface and can be detected with a specific 
antibody. To prevent the degradation of CD107a by internalization through 
endocytosis, GolgiStop is added during the co-incubation of NK cells and target cells. 
GolgiStop is a protein transport inhibitor containing monensin, which prevents 
acidification of the endosomes and thus a degradation of the CD107a molecule. 
Interleukin (IL)-2 (25U/mL)-stimulated PBMCs were coincubated with Huh7-HCVrepli-
con cells at 1:1 effector:target (E:T) ratio in the presence of anti-CD107a in order to 
assess degranulation. For the killing assay, isolated NK cells were cultivated with IL-2 
(25 U/mL) for 18 hours. Furthermore, NK cells were coincubated with eFluor670-la-
beled Huh7-HCVreplicon cells at different E:T ratios (1:1, 1:5 and 1:10). After 24 hours, 
cells were transferred to FACS tubes and 4`,6-diamidino-2-phenylindole (DAPI) was 
added before analysis. 
 
Procedure: 
- Plate 5 x 104 NK cells twice, separately, in 96-well plates  
- Stimulate cells with 25 U/ml IL-2 for 18 h 
- Transfer stimulated NK cells to each 5 x 104 Huh7-HCVreplicon cells in 48-well 
plates and add 5 µl anti-CD107a-PE immediately 
- Incubate for 60 min. 
- After incubation add 1 µl Golgi-stopp and incubate for 4 h 
- Transfer cell suspensions into FACS tubes 
- Bring to a volume of 3 ml with PBS, and centrifuge for 10 min., 300*g, RT 
- Discard supernatant and resuspend cells in 150 ml PBS 
- Perform cell surface staining with 5 µl anti-CD56-APC, 1 µl anti-CD3-PerCP1 and 1 
µl DAPI (20 sec. before measurement) 
- Incubate in the dark for 20 min., RT 
- Bring to a volume of 3 ml, with PBS and spin down for 10 min., 300*g, RT 
- Discard supernatant and fix cells in Cellfix 
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- Analyse immediately or store cells in the dark at 4 °C, for 24 h max. 
3.10 Cell culture / Human hepatoma 7 (Huh7) HCVreplicon cells 
For a long time there was no suitable cell culture system to study hepatitis C virus 
replication. In our study we used the Huh7-HCVreplicon cell system. Replicon is a DNA 
or RNA sequence, which enables independent replication. Here, the HCV subgenomic 
replicon was constructed from viral RNA isolated from the liver of an infected individual. 
The replicon has a G418 (Neomycin) resistance and encodes also a luciferase reporter 
gene for the quantitation of hepatitis C virus replication. This cell culture system with 
replicating HCV-RNA allows for both, the inhibition of the virus replication as well as 
better research and understanding of the defense mechanisms of the effector cells 
[49], [50]. 
The Huh7-HCVreplicon cells were kindly provided by V. Lohmann and R. Barten-
schlager (University of Heidelberg, Heidelberg, Germany). Cells were cultivated in an 
incubator at 37°C and 5% CO2 and were grown in high-glucose Dulbecco’s modified 
Eagle’s medium (4.5 g/l) supplemented with glutamine, 10% fetal calf serum, 1% non-
essential amino acids, and 1% penicillin/streptomycin. Blasticidin S hydro- chloride (3 
lg/ml) and G418 (1 mg/ml) were added to cells containing subgenomic replicons. Huh7-
HCVreplicon cells were passaged twice a week. 
3.11 Antiviral Activity Assay (Luciferase)  
Huh7-HCVreplicon cells were seeded in 12-well plates. After 3 hours, medium was 
removed and replicon cells were co-cultured with PBMC and purified NK- or NK-like T 
cells at different E:T ratios overnight in the absence or presence of IL-2 (25 U/ml) or 
IL-12 (1ng/ml) and IL-15  (10 ng/ml). In some experiments Huh7-HCVreplicon cells 
were cultivated for 24 hours with supernatants obtained from the corresponding direct 
co-culture experiments. The assay was performed using the Steady-Glo Luciferase 
Assay System and luminescence was measured with Tecan infinite M200. Part of the 
resulting supernatants from the co-culture was also collected for determination of as-
partate aminotransferase (AST) levels as marker for cell damage.  
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3.12 Blocking Experiments with mAbs   
In order to analyze a functional correlation of NKp46 and NKG2D regarding the 
activation of the NK cells via these receptors and the possibility of IFN-g to block viral 
replication in vitro in Huh7-HCVreplicon cells, neutralizing antibodies were used to 
block these molecules during the effector: target co-incubation. 
3.13 Statistical Analysis 
The measured results were obtained on FACS Canto II and recorded as FCS files in 
a logarithmically scaled format. The evaluation was conducted with FlowJo Version 
7.5.5. Statistical analysis was performed using the software GraphPad Prism Version 
5.0a. Wilcoxon–Mann–Whitney test was used to compare NK-cell phenotype, cytotoxic 
activity, cytokine levels, and HCV replication activity. Unpaired t-tests were carried out 
in order to calculate the statistical significance. Correlations were analyzed using linear 
regression. A two-sided P value of less than 0.05 was considered significant (*p ≤ 0.05, 
**p ≤ 0.01, ***p ≤ 0.001). 
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4 Results 
4.1 Frequency and phenotype of NK cells in acute hepatitis C in HIV+ patients 
At the beginning of our study we determined the influence of acute HCV infection on 
the NK cell pool composition as well as the phenotype of the cells. Here, we compared 
circulating NK cells from HCV acutely infected patients (HIV/aHCV) with HIV+ mono-
infected patients (HIV), HIV+ patients with an established chronic HCV infection 
(HIV/cHCV) and healthy individuals.  
Patients with acute HCV/HIV co-infection displayed the lowest frequency of all circu-
lating NK cells compared to the control groups, whereas numbers of CD56bright NK 
cells were increased. However, statistical significance was found only with respect to 
healthy individuals (Fig. 1A).  
Differences in NK cell populations did not reach statistical significance when patients 
with different outcomes of acute HCV infection were analyzed separately (Fig. 1B). 
Then, we studied the surface expression of differentiation/maturation markers on NK 
cells. Among all examined markers (CD57, CD62L, CD127 and CD161), we found that 
patients with a self-limited course of acute HCV infection expressed significantly higher 
numbers of CD62L in NK cells, both in the CD56bright and CD56Dim NK cell subpop-
ulations, than patients who developed chronic infection (Fig. 1D). No other significant 
differences were observed regarding the other markers (Fig. 1C/E/F). 
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Fig. 1 Distribution of NK cells in acute hepatitis C in HIV+ patients. (A) Comparison 
of percentages of total peripheral NK cells (left panel), CD56Dim (middle panel) and 
CD56bright (right panel) NK cells in HIV+ patients with chronic (n=12) or acute (n=27) 
HCV, in HIV+ mono-infected patients (n=8) and healthy controls (n=12). (B) Comparison 
of the percentages of total peripheral NK cells (left panel), CD56Dim (middle panel) and 
CD56bright (right panel) NK cells in HIV+ patients with a self-l imited (n=10) and chronic 
(n=17) course of HCV infection. (C/D/E/F) Frequency of total NK cells (left panel), 
CD56Dim (middle panel) and CD56bright (right panel) NK cells expressing CD57, CD62L, 
CD127 and CD161 respectively, in HIV+ patients with a self-l imited (n=10) and chronic 
(n=16) course of HCV infection. *P≤0.05, **P≤0.01, ***P≤0.001  
4.2 Peripheral NK cells are activated in acute hepatitis C/HIV co-infection 
Our next step was to examine whether HCV infection was associated with altered ac-
tivation levels of NK cells and their functional potency. Our analysis regarding the func-
tional activity of NK cells revealed a significantly stronger degranulation in patients with 
acute hepatitis C compared to the control groups (Fig. 2A). Furthermore, NK cells from 
acutely infected patients showed the strongest expression of the activation marker 
CD69 (Fig.2B).  
When patients with different outcomes of aHCV were analyzed separately we found 
weaker induction of CD107a (Fig. 2C) but higher expression of CD69 (Fig. 2D) in pa-
tients who subsequently cleared the infection. 
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Fig. 2 Circulating NK cells are activated in acute hepatitis C/HIV co-infection. (A) 
Shows the percentage of degranulation (CD107a) after IL-2 stimulation as well as CD69 
expression (B) on total NK cells, CD56Dim and CD56bright NK cells in HIV+ patients with 
chronic (n=11) or acute (n=27) HCV, in HIV mono-infected patients (n=9) and healthy 
individuals (n=12). (C) Compares the percentage of degranulation (CD107a) as well as 
CD69 expression (D) on total NK cells, CD56Dim and CD56bright in patients with a self-
l imited (closed circles) and chronic course (open circles) of acute HCV infection in HIV+ 
patients. 
4.3 Spontaneous clearance of acute hepatitis C is dependent on robust anti-
HCV NK cell activity 
In order to clarify if there were any differences in NK cell functions with respect to the 
outcome of the hepatitis C infection we co-incubated IL—2-stimulated NK cells with 
Huh7-HCVreplicon cells. We found a significantly higher frequency of degranulating 
CD56bright NK cells (Fig. 3A) as well as a significantly higher efficacy of NK cells in 
inhibiting HCV replication in vitro (Fig. 3B/C) in patients with self-limited hepatitis C 
infection than in patients who developed a chronic course of infection.   
Inhibition of HCV replication was not correlated to the extent of cytolytic activity of NK 
cells, because we could not observe any correlation between degranulation and inhi-
bition of HCV replication in the replicon cells (Fig. 3D).   
In line with this findings, we did also not find, even at high 1:1 E:T ratio, any relationship 
between inhibition of HCV replication and NK cell cytotoxicity, when we analyzed spe-
cific lysis in the killing assays and AST levels, respectively (Fig. 3E/F). These obser-
vations suggest that non-cytolytic mechanisms could play a more important role in anti-
HCV NK cell activity. 
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Fig. 3  Spontaneous clearance of acute HCV infection in HIV+ patients is associated 
with an effective NK cell-mediated inhibition of HCV replication. (A) Shows degran-
ulation rates of IL-2-stimulated NK cells acquired from patients with a self-l imited (n=10) 
and chronic course (n=15) of acute HCV infection after co-incubation with Huh7-
HCVreplicon  cells. (B) Inhibit ion of luciferase activity (LU) after co-incubation of Huh7-
HCVreplicon  cells with NK cells from patients with a self-l imited (n=10) and chronic 
course (n=16) of acute HCV infection. (C) Comparison of inhibit ion of luciferase activity 
(LU) after co-incubation of Huh7-HCVreplicon  cells with NK cells from patients with a 
self-l imited and chronic course of acute HCV infection at different E:T ratios. (D) Corre-
lation of CD107a+ NK cells (left panel), CD56Dim (middle panel) and CD56bright (right 
panel) NK cells and NK cell mediated inhibit ion of HCV replication in replicon cells. (E) 
Shows the AST levels in the supernatants of the NK cell / Huh7-HCVreplicon  cells co-
culture at different E:T ratios contrasted to inhibit ion of HCV replication. (F) NK cell-
mediated specific lysis of Huh7-HCVreplicon  cells at different E:T ratios contrasted to 
inhibit ion of HCV replication. *P≤0.05, **P≤0.01, ***P≤0.001 
4.4 Spontaneous clearance of acute hepatitis C in HIV+ patients is associated 
with a strong IFN-g mediated anti-HCV activity of NK cells 
As result of the previous findings we then studied whether soluble factors are respon-
sible for NK cell-mediated inhibition of HCV replication favoring cure of acute hepatitis 
C. Therefore, we analyzed IFN-g since this cytokine has strong antiviral activity. 
First, we analyzed the potential of NK cell capacity to produce IFN-g after IL-12/IL-15 
stimulation and we found significantly higher numbers of CD56bright NK cells with IFN-
g secretion from patients who spontaneously cleared the infection than in patients with 
a chronic course of infection (Fig. 4A).   
Moreover, we found a positive correlation between IFN-g secretion in NK cells and in-
hibition of replication in the HCV replicons, supporting a role of this cytokine in anti-
HCV NK cell activity (Fig. 4B).  
In order to validate these observations, we performed further experiments. In line with 
the prior results we studied IFN-g concentrations in supernatants after co-incubation of 
NK cells with Huh7-HCVreplicon cells. We found significantly higher concentrations of 
IFN-g in the supernatants from patients who spontaneously cleared HCV infection com-
pared to patients developing chronic HCV infection (Fig. 4C). Consequently, superna-
tants of NK cells from patients with a self-limiting course of HCV infection showed sig-
nificantly greater ability to inhibit viral replication than supernatants from patients who 
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progressed to chronic hepatitis C infection (Fig. 4D). Additionally, in vitro anti-HCV 
activity of NK cells from patients who cleared hepatitis C virus naturally was signifi-
cantly diminished after co-incubation with a specific IFN-g antibody and decreased to 
the same level of inhibition of HCV replication with patients who progressed towards 
chronic infection (Fig. 4E). 
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Fig. 4 IFN-g is critically involved in NK cell-mediated inhibition of HCV replication. 
(A) NK cells from patients with a self-l imited (n=10) and chronic course (n=15) of acute 
hepatit is C infection were stimulated with IL-12 and IL-15 in order to assess their capacity 
to secrete IFN-g. (B) Correlation of cytokine induced IFN-g secretion of total NK cells (left 
panel), CD56Dim (middle panel) and CD56bright (right panel) NK cells and inhibit ion of 
HCV replication (LU). (C) After co-incubation of NK cells from patients with different out-
comes of acute HCV infection in follow up (self-l imited n=9 and chronic course n=10) with 
Huh7-HCVreplicon  cells, supernatants were collected and tested for IFN-g  release by 
ELISA. (D) Following co-incubation of NK cells with Huh7-HCVreplicon  cells, superna-
tants were collected and tested for their abil i ty to block HCV replication (self-l imited n=9 
and chronic course n=10). (E) I l lustrates the distribution of the effect of IFN-g blockade 
on NK cell-mediated anti-HCV activity in patients with a self-l imited course (n=10) of 
acute HCV infection (left graph) and the impact of a specific IFN-g neutralizing antibody 
on anti-HCV activity of NK cells obtained from patients with a self-l imited (n=9) and 
chronic course (n=10) of acute hepatit is C (right graph). The percentage of inhibit ion LU 
was calculated using cross-multiplication between samples and controls *P≤0.05, 
**P≤0.01, ***P≤0.001 
4.5 Receptors NKG2A, NKG2C and CD158e are not involved in anti-HCV activ-
ity of NK cells 
The activity of NK cells is regulated by activating as well as inhibiting receptors. In 
order to elucidate whether the ability to clear the HCV infection in its early stage is 
related to the expression of different NK cell receptors we analyzed the surface ex-
pression of NK cells. We found that NK cells from patients with a self-limited course of 
acute hepatitis C expressed significantly higher levels of NKG2A, while expression of 
NKG2C and CD158e was reduced when compared with patients with a chronic course 
of AHC infection (Fig. 5). Further statistical analysis showed no correlation between 
expression of CD158e and NKG2A, and anti-HCV activity of NK cells (Fig. 5A/B right 
graphs). The frequency of NKG2C was inversely correlated with anti-HCV NK cell func-
tions like IFN-g secretion and in vitro inhibition of HCV replication (Fig. 5C), implying 
that these receptors are not involved in antiviral activity against HCV.  
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Fig. 5. Expression of CD158e, NKG2A and NKG2C in aHCV/HIV co-infection. 
Comparison of CD158e, NKG2A and NKG2C expression on NK cells respectively, in pa-
tients with a self-l imited and chronic course of acute hepatit is C virus infection. Correla-
tion of frequency of these markers with NK cell anti-HCV activity (A/B/C) as well as cor-
relation of the frequency of NKG2C+ NK cells with the proportion of IFN-g+ NK cells (C).  
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4.6 NKp46 and NKG2D regulate antiviral NK cell activity and may influence 
outcome of acute hepatitis C infection 
Unlike the hitherto characterized NKRs, we observed a direct role of NKp46 and 
NKG2D strengthening the inhibition of HCV replication in the replicon cells. We found 
expression of both activating NK cell receptors NKp46 and NKG2D to be expressed in 
significantly higher quantities on NK cells from patients who naturally cleared the in-
fection compared to patients who subsequently developed chronic hepatitis C infection 
(Fig. 6A). Of note, the expression of both receptors was positively correlated with IFN-
g production as well as the extent of NK cell-mediated blocking of HCV replication in 
vitro, underlining an important role for anti-HCV NK cell activity (Fig. 6B). Lastly, the 
functional roles of NKp46 and NKG2D were confirmed by blocking experiments. After 
blocking NKp46 and NKG2D with specific mAbs we observed significantly lower NK 
cell-mediated inhibition of HCV replication in vitro (Fig. 6C). 
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Fig. 6. NKp46 and NKG2D are involved in anti-HCV activity of NK cells in acute 
HCV/HIV co-infection. (A) Frequency and density (RFI) of NKp46 and NKG2D surface 
expression on NK cells from patients with a self-l imited and chronic course of acute 
HCV/HIV co-infection. (B) Correlation between frequency and density of NKp46 / NKG2D 
and inhibit ion of HCV replication or proportion of IFN-g+ NK cells in HIV+ patients with 
an acute hepatit is C virus infection. (C) Effect of blockade of NKp46 and NKG2D recep-
tors with specific neutralizing antibodies. *P≤0.05, **P≤0.01, ***P≤0.001 
4.7 Frequency and phenotype of NK-like T cells in acute hepatitis C in HIV+ 
patients 
Next, we analyzed the influence of acute HCV infection on the NK-like T cell pool as 
well as the phenotype of the NKT-cells. Here, we compared circulating NK-like T cells 
from HCV acutely infected patients (HIV/aHCV) with HIV+ mono-infected patients 
(HIV), HIV+ patients with an established chronic HCV infection (HIV/cHCV) and 
healthy individuals. We did not observe any significant differences in the NK-like T cell 
pool among our study groups (Fig. 7A). However, we found significantly higher per-
centages of CD158b and NKG2A expression on NK-like T cells in patients with HCV 
infection than in the control groups (Fig. 7B). We did not observe any other differences 
regarding the expression of NKG2C and NKG2D between the studied groups (Data 
not shown). Of note, when NK-like T cells from patients with different outcomes of 
acute hepatitis C infection were analyzed separately, we found self-limiting course to 
be associated with a significant lower expression of NKG2C (Fig. 7C).  
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Fig. 7 NK-like T cell frequency as well as expression of C-type lectin and KIR receptors 
in peripheral blood in HIV+ patients with acute hepatitis C. (A) Frequency of peripheral NK-
like T cells in healthy controls (n=12), in HIV mono-infected patients (n=8) and HIV+ patients with acute 
(n=36) or chronic (n=12) hepatitis C infection. (B) Percentage of NKG2A+ and CD158b+ NK-like T Cells 
in healthy controls (n=12), in HIV mono-infected patients (n=8) and HIV+ patients with acute (n=36) or 
chronic (n=12) hepatitis C infection. (C) Percentage of NKG2C+ NK-like T cells in HIV+ patients with a 
self-limited (n=13) and chronic course (n=21) of acute hepatitis C virus infection. *P≤0.05, **P≤0.01, 
***P≤0.001 
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4.8 Expression of maturation markers on NK-like T cells in acute HCV/HIV co-
infection 
The analysis of the maturation/differentiation markers revealed that acute hepatitis C 
in HIV+ patients is associated with a significantly reduced fraction of CD161+ NK-like 
T cells compared to the other control groups. In contrast, NK-like T cells from patients 
with HIV infection expressed significantly lower CD27 and CD127 irrespective of HCV 
co-infection (Fig. 8). Regarding the expression of these markers in patients with differ-
ent outcomes of acute hepatitis C infection, we could not observe any significant 
changes (Data not shown).  
 
Fig. 8 Expression of maturation markers on CD3(+)CD56(+) NK-like T cells. Graph 
shows surface expression of the maturation/differentiation markers CD27, CD62L, CD127 
and CD161 on NK-like T cells from healthy controls(n=12), HIV+ mono-infected patients 
(n=8) and HIV+ patients with acute (n=36) or chronic (n=12) hepatitis C infection. 
*P≤0.05, **P≤0.01, ***P≤0.001 
 
0
20
40
60
80
100 *
***
n.s.
n.s. 
n.s. n.s. 
n.s. n.s. 
n.s. 
n.s. 
CD27 CD62L
%
po
si
tiv
e
C
D
3(
+)
C
D
56
(+
) N
K
-li
ke
 T
 c
el
ls
22.3% 15.7%
17.7%61.3%
healthy HIV
HIV/aHCV HIV/cHCV
CD3
CD
62
L
29.9%
6.12%
24.3%
27.2%
healthy HIV
HIV/aHCV HIV/cHCV
CD3
88.0% 12.1%
17.2%11.3%
healthy HIV
HIV/aHCV HIV/cHCV
CD3
CD
27
73.0% 16.0%
14.1% 26.6%
healthy HIV
HIV/aHCV HIV/cHCV
CD3
CD
12
7
CD
16
1
***
**
**
***
*
** *
**
n.s. 
n.s. 
CD127 CD161
0
20
40
60
80
100
%
po
si
tiv
e
C
D
3(
+)
C
D
56
(+
) N
K
-li
ke
 T
 c
el
ls
Results 
 
 
38 
 
4.9 Peripheral NK-like T cells are activated in acute hepatitis C/HIV co-infec-
tion 
Our next step was to clarify whether HCV infection was associated with the activation 
level of NK-like T cells in acute HCV/HIV co-infection. Since the number of available 
lymphocytes was too low to isolate NK-like T cells from the patients, we performed the 
experiments with PBMCs. Our analysis regarding the cytotoxic activity of NK-like T 
cells revealed a significantly stronger degranulation (CD107a) in patients with acute 
hepatitis C compared to HIV mono-infected as well as HIV+ patients with chronic hep-
atitis C infection. When patients with different outcomes of acute HCV were analyzed 
separately we did not observe any differences (Fig. 9A). Furthermore, NK-like T cells 
from acutely infected patients showed the highest expression of the activation marker 
CD69 when compared to healthy individuals and HIV mono-infected patients. Moreo-
ver, we found patients with a self-limited course of HCV infection to display significantly 
higher expression of CD69 than patients with a chronic course of infection (Fig.9B).
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Fig. 9 Degranulation (CD107a) and activation level (CD69) of NK-like T cells in HIV+ 
patients with acute hepatitis C infection. (A) Degranulation of circulating NK-like T 
cells after co-incubation with Huh7-HCVreplicon  cells in healthy controls (n=12), HIV+ 
mono-infected patients (n=8) and HIV+ patients with acute (n=36) or chronic (n=11) hep-
atit is C (left graph) and in HIV+ patients with a self-l imited (n=13) or chronic (n=23) 
course of acute hepatit is C infection (right graph). (B) Activation level as defined by CD69 
expression of peripheral NK-like T cells in healthy controls (n=12), HIV+ mono-infected 
patients (n=8) and HIV+ patients with acute (n=36) or chronic (n=7) hepatit is C (left 
graph) and in HIV+ patients with a self-l imited (n=13) or chronic (n=23) course of acute 
hepatit is C infection (right graph). *P≤0.05, **P≤0.01, ***P≤0.001 
4.10 HIV infection impairs the ability of CD3(+)CD56(+) NK-like T cells to inhibit 
HCV replication  
Despite the fact that we did not find phenotypic alterations apart from upregulated ex-
pression of CD69 to be associated with spontaneous clearance, we also analyzed 
functions of CD3(+)CD56(+) NK-like T cells and their capacity to inhibit HCV replica-
tion. We found that unstimulated CD3(+)CD56(+) NK-like T cells from healthy donors 
displayed moderate inhibition of HCV replication, whereas IL-12/IL-15 stimulation sig-
nificantly enhanced their antiviral capacity (Fig. 10A).  
To elucidate whether CD3(+)CD56(+) NK-like T cells-mediated inhibition of HCV rep-
lication was cell-cell contact dependent we performed further experiments with the su-
pernatants from the corresponding co-incubation experiments of CD3(+)CD56(+) NK-
like T cells x Huh7-HCVreplicon cells. We found that supernatants from IL-12/IL-15 
stimulated cells inhibited viral replication significantly more effectively than superna-
tants from resting NK-like T cells suggesting that non-cytolytic factors are involved in 
this mechanism (Fig. 10B). In support of this observation, we found only a negligible 
killing-activity (specific lysis, AST levels) of CD3(+)CD56(+) NK-like T cells after co-
incubation with Huh7-HCVreplicon cells (Fig. 10C) but observed significantly increased 
production of IFN-g after IL-12/IL-15 stimulation (Fig. 10D). We also found that 
CD3(+)CD56(+) NK-like T cell-dependent inhibition of HCV replication in HCV replicon 
cells as well as IFN-g secretion were reduced after neutralization with a specific IFN-g 
antibody (Fig. 10E). Finally, IL-12/IL-15 stimulated CD3(+)CD56(+) NK-like T cells from 
HIV infected patients showed significantly reduced efficacy inhibiting HCV replication 
in vitro as well as IFN-g production when compared with cells from healthy controls 
(Fig. 10F/G).  
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Fig. 10 The anti-HCV activity of NK-like T cells is impaired in HIV+ patients. (A) 
Unstimulated or IL-12/IL-15 pre-stimulated, isolated NK-like T cells from healthy donors 
(n=7) were co-incubated with Huh7-HCVreplicon  cells over night at different E:T ratios in 
order to analyze their anti-HCV abil ity. (B) Supernatants from co-incubation of NK-like T 
cells / Huh7-HCVreplicon  cells were analyzed with respect to inhibit ion of HCV replication 
(n=7). (C) NK-like T cell-mediated cytotoxicity and AST levels in supernatants were 
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measured after co-incubation of NK-like T cells with Huh7-HCVreplicon  cells. (D) Unstim-
ulated or IL-12/IL-15 pre-stimulated NK-like T cells from healthy donors (n=7) were tested 
for IFN-g production. (E) Distribution of the effect of IFN-g blockade on NK-like T cell-
mediated anti-HCV activity in healthy donors (n=4). (F) NK-like T cells from healthy do-
nors (n=7) and HIV+ patients (n=7) were stimulated with IL-12/IL-15 and then co-incu-
bated with Huh7-HCVreplicon  cells to analyze their abil i ty to block HCV replication. (G) 
NK-like T cells from healthy donors (n=12) and HIV+ patients (n=8) were stimulated with 
IL-12/IL-15 and then tested for IFN-g production. *P≤0.05, **P≤0.01, ***P≤0.001 
4.11 CD3(+)CD56(+) NK-like T cells from HIV-positive patients with acute HCV 
infection display reduced IFN-g Production  
In order to clarify whether CD3(+)CD56(+) NK-like T cells play a decisive role concern-
ing outcomes of acute hepatitis C in HIV infected patients, we analyzed their IFN-g 
production. As shown in Fig. 11, IL-12/IL-15 stimulated CD3(+)CD56(+) NK-like T cells 
in acute HCV/HIV infection were associated with significantly lower IFN-g production 
compared to all other control groups. Importantly, we did not find any significant differ-
ences in IFN-g production between patients who spontaneously cleared their infection 
vs. patients who developed chronic HCV infection when isolated CD3(+)CD56(+) NK-
like T cells were analyzed separately. 
 
 
 
 
 
 
 
 
 
Fig. 11 IFN-g production of NK-like T cells in HIV+ patients with acute hepatitis C. 
NK-like T cells from healthy donors (n=12), HIV+ mono-infected patients (n=8) and HIV+ 
patients with acute (n=36) or chronic (n=12) hepatit is C infection (left graph) as well as 
HIV+ patients with self-l imited (n=13) or chronic (n=23) course of hepatit is C infection 
(right graph) were stimulated with IL-12/IL-15 and then analyzed with respect to IFN-g 
production.  *P≤0.05, **P≤0.01, ***P≤0.001  
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5 Discussion  
Despite the pre-existing HIV infection, a small proportion of acute HCV infected pa-
tients can spontaneously clear their hepatitis C virus infection during the acute phase 
and completely eliminate the virus spontaneously. Until now, the mechanisms that fa-
vor spontaneous (natural) clearance are not understood sufficiently. 
Numerous studies indicated an important role for NK cells during hepatitis C infection, 
and recent analysis from several groups suggested distinct subpopulations to be in-
volved in the early stage and determining outcomes of HCV infection [29], [30], [34]–
[36], [51]–[55] . In our work we focused on frequency, phenotypes and functional alter-
ations of NK and NKT cells and correlated them to spontaneous clearance of the acute 
HCV infection in HIV-positive patients. It should be noted that we are the only group 
that investigated the role of NK and NKT cells in acute hepatitis C / HIV co-infection.  
All previous studies were conducted on acute HCV mono-infection [29], [35], [36]. First, 
we wanted to analyze whether HCV infection has an impact on the relative abundance 
and distribution of the NK cells and their subsets. At this point, we found a decline on 
CD56Dim NK cells in acute hepatitis C when compared to healthy controls, which was 
in line with the results of other groups. While Pelletier et. al. and Alter et. al did not find 
any differences in the CD56Bright NK cell fraction, Amadei and our group, observed 
increased numbers of CD56Bright NK cells in resolvers when compared to healthy 
donors [29], [35], [36]. The total numbers of NK cells in acute hepatitis C varied also 
between the different studies, while Amadei et. al. and our group found a depletion in 
aHCV infection which was in contrast to the findings of Alter et. al. [29], [35].  Pelletier 
et al. suggested that these differences in the composition of the NK cell pool might be 
an effect of a persistent stimulation of the CD56Dim cells or a switch to activated 
CD56Bright NK cells [36]. In contrast, other studies on NK cells showed that it is more 
likely that CD56Bright cells show CD56Dim NK cells features after stimulation [56]. 
Consequently, the role of NK cells in acute hepatitis C is still discussed controversially 
owing to the divergent data. Therefore, more studies on the frequency and composition 
of NK cells are needed to understand differences in recruitment between peripheral 
NK cells and liver resistant NK cells in hepatitis C infection. Despite the fact that the 
frequency of NK cells in peripheral blood may reveal only vague information, the func-
tional properties of these cells are considered to be pivotal for the spontaneous cure 
of acute hepatitis C in HIV+ patients. 
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Although all previous studies in acutely HCV mono infected patients showed also sig-
nificant differences in phenotype and activity of NK cells, they did not find any correla-
tions between NK cell functions and outcomes of acute HCV infection [29], [35], [36]. 
Recently, we and others have already shown that non-cytotoxic functions of NK cells 
as well as HCV-specific CD8+ T cells are critically involved in the control of chronic 
hepatitis C infection [34], [57]. Here we provided first evidence showing that NK cells 
are critically involved in outcome of acute HCV infection favoring spontaneous clear-
ance by blocking the hepatitis C virus replication. We present a cascade of evidence 
suggesting IFN-g secretion of NK cells to be a key parameter for the outcome of acute 
HCV infection. We show IL-12/IL-15-induced IFN-g secretion to be significantly higher 
in CD56bright NK cells from resolvers compared to chronic patients. The frequency of 
IFN-g+ NK cells was positively correlated with in vitro anti-HCV activity of NK cells 
against HCV replicon cells while NK cell in vitro degranulation (CD107a) did not reveal 
any correlation between NK cell cytolytic activity and inhibition of HCV replication. In 
line with this, we demonstrated a significantly higher concentration of IFN-g in super-
natants from patients who spontaneously resolved HCV infection after co-incubation 
with Huh7-HCVreplicon cells compared to supernatants from patients who developed 
a chronic course of infection. Furthermore, supernatants from resolvers showed a sig-
nificantly higher ability to inhibit HCV replication in vitro and neutralization with a spe-
cific anti-IFN-g antibody inhibited this phenomenon compared to patients who subse-
quently developed chronic infection.  
Taken together, these findings indicate a key role for IFN-g secretion from NK cells in 
anti-HCV activity, suggesting a possible mechanism which supports spontaneous 
clearance of infection in the early acute phase. Our results correspond with observa-
tions made in CD8+ T cells during HCV mono infection where IFN-g production in liver 
was correlated with decreased HCV RNA levels [58]. In addition, accumulation of HCV 
specific IFN-g producing CD8+ T cells in livers of patients without significant disease 
further supports a non-cytolytic pathway in the acute phase of the infection [59], [60]. 
Nevertheless, all other groups who worked on acute HCV infection could not find any 
significant differences between IFN-g capacities of NK cells and outcomes of HCV in-
fection. Amadei et. al. and Alter et. al. even showed that CD56Dim NK cells tended to  
exert more IFN-g compared to their counter partners CD56Bright NK cells. Pelletier et. 
al. did not observe any changes at all [29], [35], [36].  
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These differences between our results and those of the other groups could be due to 
contrasting stimulations of the NK cells. Pelletier et. al. and Alter et. al. stimulated the 
NK cells with K562 and 221 target cells without prior cytokine stimulation, while Amadei 
et. al. used IL-12 as stimulator in their experiments and we used both cytokines IL-12 
and IL-15 to achieve maximum stimulation. In our experiments, patients with acute 
HCV infection could also secrete higher amounts of IFN-g compared to patients in 
Amadei et. al., an observation which may be linked to the long-term activation by the 
persisting HIV infection in our cohort. However, according to our results stimulation 
with cytokines seems to be the better way to analyze the capacity of NK cells to pro-
duce IFN-g.   
Next, our laboratory analysis of blood revealed significantly higher alanine transami-
nase (ALT) and aspartate transaminase (AST) levels in patients with acute hepatitis C 
than in patients with chronic hepatitis C infection. However, our specific in vitro lysis 
experiments regarding cytotoxic activity of NK cells against Huh7-HCVreplicon cells 
could not explain the findings in the blood of infected patients. We found a strong NK 
cell-mediated inhibition of HCV replication in the presence of minimal cytolysis as well 
as mild AST levels even at high E:T ratios, suggesting that cytotoxic activity of NK cells 
is not significantly involved in the defense against acute HCV infection at the very early 
stages. AST and ALT levels also did not differ when patients with acute HCV infection 
were analyzed separately with respect to the outcome of infection. Although we found 
CD56bright NK cells, the dominant intrahepatic NK cell subpopulation, to exert greater 
cytolytic activity in patients with acute resolving hepatitis C than in patients who devel-
oped chronic infection, we cannot draw conclusions on a role of these cells in the liver 
as we analyzed peripheral blood samples. Reports about “CD56Bright-killers” were 
made by Stegmann et. al. with TRAIL being the main cytotoxic molecule on these cells 
[54]. To measure the cytotoxic potency of the NK cells, we chose the Huh7-HCVrepli-
con cell system which, might be the closest model to study immune responses against 
a hepatotropic virus such as hepatitis C. In contrast, all previous studies on acute HCV 
mono-infection were conducted using hematopoietic cell lines such as K562 and/or 
221 cells as targets for cytotoxicity.  
The function of NK cells is critical dependent on the balance between inhibiting and 
activating NKRs. In recent studies of our group as well as that of Golden-Mason et al. 
it has been demonstrated that the activating NK cell receptor NKp46 is involved in 
antiviral activity of NK cells in chronic hepatitis C infection, since intrahepatic frequency 
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of this receptor was negatively correlated with hepatitis C viral loads [34], [61]. In our 
present experiments in acute HCV infection we found the prevalence of CD56bright 
NKp46+ NK cells to be significantly higher in resolvers than in the patients who pro-
gressed to chronical infection. Moreover, we found a positive correlation between the 
frequency of NKp46+ NK cells and inhibition of HCV replication as well as IFN-g secre-
tion. Finally, blocking of NKp46 with a specific antibody significantly decreased the 
ability of NK cells to inhibit viral replication in vitro, suggesting a role of this receptor in 
the early phase of acute HCV infection.  
A further important component in anti-viral activity of NK cells, which has been ana-
lyzed in many previous studies on hepatitis C infection is NKG2D. We analyzed ex-
pression and function of NKG2D in NK cells in acute HCV infection, as it has been 
shown that HCV infection leads to induction of MHC-I-like ligands of NKG2D on in-
fected hepatocytes [62]. Analogous to expression of NKp46, we found significantly 
higher surface expression of NKG2D in patients who spontaneously cleared the HCV 
infection as compared to those who developed a chronic course of infection. Moreover, 
we observed a strong correlation between expression of NKG2D and both NK cell-
mediated inhibition of HCV replication and IFN-g secretion. Finally, blocking NKG2D 
with a specific antibody significantly reduced the ability of NK cells to inhibit HCV rep-
lication in vitro strengthening a pivotal role of this receptor for resolution of acute HCV 
infection. Thus, our results provide circumstantial evidence that both activating recep-
tors NKp46 and NKG2D are critically involved in NK cell functions, especially modulat-
ing IFN-g production, in acute HCV/HIV co-infection. Consequently, spontaneous 
higher expression of both receptors may describe patients who are predisposed to 
naturally clear HCV infection in an IFN-g dependent manner during the course of acute 
infection.  
Previous studies analyzed the role of NK cells in acute HCV mono-infection and had 
controversial results. For example, Alter et al. found a correlation between low expres-
sion of NKp46 and NKG2D and spontaneous clearance of HCV infection, suggesting 
that this might be a consequence of receptor downregulation following NK cell activa-
tion by this receptor (NKG2D). Amadei et al. failed to demonstrate any correlation [29], 
[35]. Interestingly, Sene et al. described down regulation of NKG2D in chronic HCV 
mono-infection to lead to impaired IFN-g secretion and NK cell cytotoxic activity as a 
potential viral escape mechanism of HCV.  
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Again these findings emphasize a pivotal role of this receptor for control of HCV infec-
tion by NK cells, which is in line with our results also in acute HCV infection [62]. Nev-
ertheless, further analysis is required to understand the exact mechanisms, which re-
sult in up or down regulation of activating NK cell receptors in acute HCV infection. 
A critical issue in the interpretation of our results is the fact that HIV infection existed 
prior to acute hepatitis C. Thus, it remains unclear whether our results can be trans-
ferred to HCV mono-infection or whether they are specific for HIV/HCV coinfection. 
However, we could not observe any significant differences among our patients’ char-
acteristics, such as CD4+ T cell counts, age, gender, IL28B genotype and other pa-
rameters, which could explain the differences in NK cell phenotypes and functions on 
the outcome of acute HCV infection. HIV mono-infection alone has been described to 
lead to alterations in NK cell phenotype and function. Although all HIV positive patients 
in our studies were under efficient antiretroviral therapy, changes in NK cell biology 
due to HIV infection were not fully reversed; so that at least some of our observations 
are likely to be specific for HIV/HCV co-infection.   
CD3(+) CD56(+) NK-like T cells are lymphocytes, which share characteristics from 
both NK cells and T cells [39], [40]. Of note, also this cell type has been described to 
control the outcome of acute HCV mono infection [41]. The reports on NK-like T cells 
and our present findings in NK cells, encouraged us to analyze the CD3(+) CD56(+) 
NK-like T cells also in HIV patients with acute hepatitis C. In our experiments, we 
wanted to clarify whether NK-like T cells also contribute to the mechanisms that affect 
outcomes of acute HCV infection in HIV+ patients.  
IFN-g is critically involved in the anti-HCV activity of lymphocyte populations [34], [57]. 
Here our work, demonstrates that IFN-g is also a key element how CD3(+) CD56(+) 
NK-like T cells contribute to anti-HCV activity in early HCV infection. First, we showed 
that IL-12/IL-15 stimulated NK-like T cells from healthy individuals can effectively block 
HCV replication after co-incubation with Huh7-HCVreplicon cells. Secondly, we found 
that supernatants from NK-like T cells also efficiently inhibit HCV replication indicating 
that anti-HCV activity of these cells is not mediated by a cell-cell contact dependent 
mechanism. This observation was further confirmed, because we found minimal cyto-
lytic activity as well as low AST levels after co-incubation of NK-like T cells with Huh7-
HCVreplicon cells even at high E:T ratios.  
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Third, we observed that stimulated NK-like T cells produced significantly more IFN-g 
than unstimulated cells and blocking of IFN-g with a specific antibody significantly de-
creased the ability of NK-like T cells to inhibit HCV replication in vitro. Despite blocking 
of IFN-g a substantial anti-HCV activity of NK-like T cells was found suggesting that 
other soluble factors than IFN-g to be involved in antiviral activity.   
HIV infection has already been described to be associated with phenotypical and func-
tional changes of CD3(+) CD56(+) NK-like T cells [45], [46]. Furthermore, Montoya et 
al. showed a shift in NK-like T cell pool, because they found significantly decreased 
numbers of NK-like T cells in HIV patients compared with healthy individuals [46]. In-
deed, we could not observe any similar alterations in our studied groups with respect 
to the frequency of NK-like T cells. Moreover, we observed functional dysregulation of 
NK-like T cells to be correlated with the HIV infection, because we found NK-like T 
cells from HIV patients to display significantly decreased IFN-g production compared 
with healthy individuals. Our observation is in line with a prior report presented by Jiang 
et al. [45] who suggested that HIV infection was linked to chronic immune activation, 
which further leads to functional inactivation. On the other hand, in acute HCV mono-
infection Golden Mason et al. showed a correlation between an activated phenotype 
of CD3(+) CD56(+) NK-like T cells and outcome of acute hepatitis C, which was favor-
ing spontaneous clearance of infection [41]. Corresponding to this observation, we 
found CD69 to be significantly higher expressed on NK-like T cells from patients with 
a self-limited course of acute HCV infection than in HIV+ patients who subsequently 
developed chronic course. Since we could not find any correlation between CD69 ex-
pression and NK-like T cell functions and intrahepatic cells were not available to check 
the activity of NK-like T cells in the liver, it remains unclear whether NK-like T cells 
display an activated phenotype in acute hepatitis C. Thus, higher expression of CD69 
in the periphery could just represent unspecific immune activation. More importantly, 
our findings do not support major participation of NK-like T cells in spontaneous clear-
ance of acute hepatitis C in HIV patients, because in vitro we found IFN-g production 
to play a significant role for anti-HCV activity, while at the same time NK-like T cells 
from HIV(+) patients displayed impaired IFN-g production. 
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Taken together our results indicate that during the acute phase of hepatitis C infection 
in HIV positive patients a strong IFN-g response mediates inhibition of HCV replication. 
Release of IFN-g by NK cells is correlated with spontaneous clearance of HCV infec-
tion. This IFN-g secretion from NK cells is critically regulated via the activating recep-
tors NKp46 and NKG2D. Expression of these receptors defines NK cell subpopulations 
with strong anti-HCV capacity. Although NK-like T cells can also inhibit HCV replication 
in vitro, HIV infection seems to dysregulate the in vivo capacity of NK-like T cells, so 
that this cell population can contribute only little to anti-HCV defense in HIV infection.  
References 
 
 
49 
 
6 References 
[1] U. K. Widmer, A. Villaverde, and P. J. Grob, “[Epidemiology of hepatitis 1977-
1979],” Schweiz Med Wochenschr, vol. 110, no. 24, pp. 930–937, Jun. 1980. 
[2] Q. L. Choo, G. Kuo, A. J. Weiner, L. R. Overby, D. W. Bradley, and M. Hough-
ton, “Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral 
hepatitis genome,” Science, vol. 244, no. 4902, pp. 359–362, Apr. 1989. 
[3] Murphy DG, Sablon E, Chamberland J, Fournier E, Dandavino R, Tremblay CL. 
2015. Hepatitis C virus genotype 7, a new genotype originating from Central 
Africa. J Clin Microbiol 53:967–972. doi:10.1128/JCM.02831-14.  
[4] “WHO | Hepatitis C,” WHO. [Online]. Available: http://www.who.int/mediacen-
tre/factsheets/fs164/en/. 
[5] H. J. Alter et al., “Detection of antibody to hepatitis C virus in prospectively fol-
lowed transfusion recipients with acute and chronic non-A, non-B hepatitis,” N. 
Engl. J. Med., vol. 321, no. 22, pp. 1494–1500, Nov. 1989. 
[6] G. M. Robinson, J. N. Reynolds, and B. J. Robinson, “Hepatitis C prevalence 
and needle/syringe sharing behaviours in recent onset injecting drug users,” N. 
Z. Med. J., vol. 108, no. 996, pp. 103–105, Mar. 1995. 
[7] R. A. Tohme and S. D. Holmberg, “Is sexual contact a major mode of hepatitis 
C virus transmission?,” Hepatology, vol. 52, no. 4, pp. 1497–1505, Oct. 2010. 
[8] F. Barré-Sinoussi et al., “Isolation of a T-lymphotropic retrovirus from a patient 
at risk for acquired immune deficiency syndrome (AIDS). 1983,” Rev. Invest. 
Clin., vol. 56, no. 2, pp. 126–129, Apr. 2004. 
[9] Kirchhoff F. „Optimale“ Anpassung pandemischer HIV-1-Stämme an den Men-
schen. BIOspektrum | 02.10 | 16. Jahrgang                                                                   
http://biospektrum.de/blatt/d_bs_pdf&_id=1024689. 
[10] “WHO | HIV/AIDS,” WHO. [Online]. Available: http://www.who.int/mediacen-
tre/factsheets/fs360/en/. 
 
References 
 
 
50 
 
[11] Hoffmann C, Rockstroh J.K. HIV 2011. www.hivbuch.de S.4, S.7, S.536 
http://hivbuch.files.wordpress.com/2011/12/hiv-20111.pdf 
 [12] C. S. Graham et al., “Influence of human immunodeficiency virus infection on 
the course of hepatitis C virus infection: a meta-analysis,” Clin. Infect. Dis., vol. 
33, no. 4, pp. 562–569, Aug. 2001. 
[13] Y. Benhamou et al., “Liver fibrosis progression in human immunodeficiency vi-
rus and hepatitis C virus coinfected patients. The Multivirc Group,” Hepatology, 
vol. 30, no. 4, pp. 1054–1058, Oct. 1999. 
[14] I. Bica et al., “Increasing mortality due to end-stage liver disease in patients with 
human immunodeficiency virus infection,” Clin. Infect. Dis., vol. 32, no. 3, pp. 
492–497, Feb. 2001. 
[15] M. A. Cooper, T. A. Fehniger, and M. A. Caligiuri, “The biology of human natural 
killer-cell subsets,” Trends Immunol., vol. 22, no. 11, pp. 633–640, Nov. 2001. 
[16] K. Hata, D. H. Van Thiel, R. B. Herberman, and T. L. Whiteside, “Natural killer 
activity of human liver-derived lymphocytes in various liver diseases,” Hepatol-
ogy, vol. 14, no. 3, pp. 495–503, Sep. 1991. 
[17] G. Trinchieri, “Biology of natural killer cells,” Adv. Immunol., vol. 47, pp. 187–
376, 1989. 
[18] T. L. Whiteside and R. B. Herberman, “Role of human natural killer cells in 
health and disease,” Clin. Diagn. Lab. Immunol., vol. 1, no. 2, pp. 125–133, Mar. 
1994. 
[19] A. Moretta et al., “Activating receptors and coreceptors involved in human nat-
ural killer cell-mediated cytolysis,” Annu. Rev. Immunol., vol. 19, pp. 197–223, 
2001. 
[20] A. Moretta, R. Biassoni, C. Bottino, M. C. Mingari, and L. Moretta, “Natural cy-
totoxicity receptors that trigger human NK-cell-mediated cytolysis,” Immunol. 
Today, vol. 21, no. 5, pp. 228–234, May 2000. 
References 
 
 
51 
 
[21] R. Gazit et al., “Lethal influenza infection in the absence of the natural killer cell 
receptor gene Ncr1,” Nat. Immunol., vol. 7, no. 5, pp. 517–523, May 2006. 
[22] O. Mandelboim et al., “Recognition of haemagglutinins on virus-infected cells 
by NKp46 activates lysis by human NK cells,” Nature, vol. 409, no. 6823, pp. 
1055–1060, Feb. 2001. 
[23] F. Borrego, M. Ulbrecht, E. H. Weiss, J. E. Coligan, and A. G. Brooks, “Recog-
nition of human histocompatibility leukocyte antigen (HLA)-E complexed with 
HLA class I signal sequence-derived peptides by CD94/NKG2 confers protec-
tion from natural killer cell-mediated lysis,” J. Exp. Med., vol. 187, no. 5, pp. 
813–818, Mar. 1998. 
[24] V. M. Braud et al., “HLA-E binds to natural killer cell receptors CD94/NKG2A, B 
and C,” Nature, vol. 391, no. 6669, pp. 795–799, Feb. 1998. 
[25] N. Lee et al., “HLA-E is a major ligand for the natural killer inhibitory receptor 
CD94/NKG2A,” Proc. Natl. Acad. Sci. U.S.A., vol. 95, no. 9, pp. 5199–5204, 
Apr. 1998. 
[26] S. Bauer et al., “Activation of NK cells and T cells by NKG2D, a receptor for 
stress-inducible MICA,” Science, vol. 285, no. 5428, pp. 727–729, Jul. 1999. 
[27] M. Kubin et al., “ULBP1, 2, 3: novel MHC class I-related molecules that bind to 
human cytomegalovirus glycoprotein UL16, activate NK cells,” Eur. J. Immunol., 
vol. 31, no. 5, pp. 1428–1437, May 2001. 
[28] D. Cosman et al., “ULBPs, novel MHC class I-related molecules, bind to CMV 
glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor,” 
Immunity, vol. 14, no. 2, pp. 123–133, Feb. 2001. 
[29] B. Amadei et al., “Activation of natural killer cells during acute infection with 
hepatitis C virus,” Gastroenterology, vol. 138, no. 4, pp. 1536–1545, Apr. 2010. 
[30] S. I. Khakoo et al., “HLA and NK cell inhibitory receptor genes in resolving hep-
atitis C virus infection,” Science, vol. 305, no. 5685, pp. 872–874, Aug. 2004. 
References 
 
 
52 
 
[31] A. Houldsworth et al., “Polymorphisms in the IL-12B gene and outcome of HCV 
infection,” J. Interferon Cytokine Res., vol. 25, no. 5, pp. 271–276, May 2005. 
[32] P. An, C. L. Thio, G. D. Kirk, S. Donfield, J. J. Goedert, and C. A. Winkler, “Reg-
ulatory polymorphisms in the interleukin-18 promoter are associated with hepa-
titis C virus clearance,” J. Infect. Dis., vol. 198, no. 8, pp. 1159–1165, Oct. 2008. 
[33] J. Larkin, A. Bost, J. I. Glass, and S.-L. Tan, “Cytokine-activated natural killer 
cells exert direct killing of hepatoma cells harboring hepatitis C virus replicons,” 
J. Interferon Cytokine Res., vol. 26, no. 12, pp. 854–865, Dec. 2006. 
[34] B. Krämer et al., “Natural killer p46High expression defines a natural killer cell 
subset that is potentially involved in control of hepatitis C virus replication and 
modulation of liver fibrosis,” Hepatology, vol. 56, no. 4, pp. 1201–1213, Oct. 
2012. 
[35] G. Alter et al., “Reduced frequencies of NKp30+NKp46+, CD161+, and 
NKG2D+ NK cells in acute HCV infection may predict viral clearance,” J. Hepa-
tol., vol. 55, no. 2, pp. 278–288, Aug. 2011. 
[36] S. Pelletier, C. Drouin, N. Bédard, S. I. Khakoo, J. Bruneau, and N. H. Shoukry, 
“Increased degranulation of natural killer cells during acute HCV correlates with 
the magnitude of virus-specific T cell responses,” J. Hepatol., vol. 53, no. 5, pp. 
805–816, Nov. 2010. 
[37] M. Kronenberg, “Toward an understanding of NKT cell biology: progress and 
paradoxes,” Annu. Rev. Immunol., vol. 23, pp. 877–900, 2005. 
[38] D. G. Doherty and C. O’Farrelly, “Innate and adaptive lymphoid cells in the hu-
man liver,” Immunol. Rev., vol. 174, pp. 5–20, Apr. 2000. 
[39] P. H. Lu and R. S. Negrin, “A novel population of expanded human CD3+CD56+ 
cells derived from T cells with potent in vivo antitumor activity in mice with se-
vere combined immunodeficiency,” J. Immunol., vol. 153, no. 4, pp. 1687–1696, 
Aug. 1994. 
References 
 
 
53 
 
[40] D. I. Godfrey, H. R. MacDonald, M. Kronenberg, M. J. Smyth, and L. Van Kaer, 
“NKT cells: what’s in a name?,” Nat. Rev. Immunol., vol. 4, no. 3, pp. 231–237, 
2004. 
[41] L. Golden-Mason, N. Castelblanco, C. O’Farrelly, and H. R. Rosen, “Phenotypic 
and functional changes of cytotoxic CD56pos natural T cells determine outcome 
of acute hepatitis C virus infection,” J. Virol., vol. 81, no. 17, pp. 9292–9298, 
Sep. 2007. 
[42] N. Kawarabayashi et al., “Decrease of CD56(+)T cells and natural killer cells in 
cirrhotic livers with hepatitis C may be involved in their susceptibility to hepato-
cellular carcinoma,” Hepatology, vol. 32, no. 5, pp. 962–969, Nov. 2000. 
[43] J. M. Werner et al., “Innate immune responses in hepatitis C virus-exposed 
healthcare workers who do not develop acute infection,” Hepatology, vol. 58, 
no. 5, pp. 1621–1631, Nov. 2013. 
[44] E. Jouvin-Marche et al., “Lymphocytes degranulation in liver in hepatitis C virus 
carriers is associated with IFNL4 polymorphisms and ALT levels,” J. Infect. Dis., 
vol. 209, no. 12, pp. 1907–1915, Jun. 2014. 
[45] Y. Jiang et al., “The function of CD3+CD56+ NKT-like cells in HIV-infected indi-
viduals,” Biomed Res Int, vol. 2014, p. 863625, 2014. 
[46] C. J. Montoya, P. A. Velilla, C. Chougnet, A. L. Landay, and M. T. Rugeles, 
“Increased IFN-gamma production by NK and CD3+/CD56+ cells in sexually 
HIV-1-exposed but uninfected individuals,” Clin. Immunol., vol. 120, no. 2, pp. 
138–146, Aug. 2006. 
[47] A. Böyum, “Separation of leukocytes from blood and bone marrow. Introduc-
tion,” Scand. J. Clin. Lab. Invest. Suppl., vol. 97, p. 7, 1968. 
[48] G. Alter, J. M. Malenfant, and M. Altfeld, “CD107a as a functional marker for the 
identification of natural killer cell activity,” J. Immunol. Methods, vol. 294, no. 1–
2, pp. 15–22, Nov. 2004. 
References 
 
 
54 
 
[49] V. Lohmann, F. Körner, J. Koch, U. Herian, L. Theilmann, and R. Barten-
schlager, “Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell 
line,” Science, vol. 285, no. 5424, pp. 110–113, Jul. 1999. 
[50] N. Krieger, V. Lohmann, and R. Bartenschlager, “Enhancement of hepatitis C 
virus RNA replication by cell culture-adaptive mutations,” J. Virol., vol. 75, no. 
10, pp. 4614–4624, May 2001. 
[51] M. M. Dring et al., “Innate immune genes synergize to predict increased risk of 
chronic disease in hepatitis C virus infection,” Proc. Natl. Acad. Sci. U.S.A., vol. 
108, no. 14, pp. 5736–5741, Apr. 2011. 
[52] S. Knapp et al., “Consistent beneficial effects of killer cell immunoglobulin-like 
receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to 
hepatitis C virus,” Hepatology, vol. 51, no. 4, pp. 1168–1175, Apr. 2010. 
[53] A. Rauch et al., “Influence of inhibitory killer immunoglobulin-like receptors and 
their HLA-C ligands on resolving hepatitis C virus infection,” Tissue Antigens, 
vol. 69 Suppl 1, pp. 237–240, Apr. 2007. 
[54] K. A. Stegmann et al., “Interferon-alpha-induced TRAIL on natural killer cells is 
associated with control of hepatitis C virus infection,” Gastroenterology, vol. 
138, no. 5, pp. 1885–1897, May 2010. 
[55] G. Ahlenstiel et al., “Early changes in natural killer cell function indicate virologic 
response to interferon therapy for hepatitis C,” Gastroenterology, vol. 141, no. 
4, pp. 1231–1239, 1239.e1–2, Oct. 2011. 
[56] C. Romagnani et al., “CD56brightCD16- killer Ig-like receptor- NK cells display 
longer telomeres and acquire features of CD56dim NK cells upon activation,” J. 
Immunol., vol. 178, no. 8, pp. 4947–4955, Apr. 2007. 
[57] J. Jo et al., “Analysis of CD8+ T-cell-mediated inhibition of hepatitis C virus rep-
lication using a novel immunological model,” Gastroenterology, vol. 136, no. 4, 
pp. 1391–1401, Apr. 2009. 
References 
 
 
55 
 
[58] R. Thimme, D. Oldach, K. M. Chang, C. Steiger, S. C. Ray, and F. V. Chisari, 
“Determinants of viral clearance and persistence during acute hepatitis C virus 
infection,” J. Exp. Med., vol. 194, no. 10, pp. 1395–1406, Nov. 2001. 
[59] N. H. Shoukry et al., “Memory CD8+ T cells are required for protection from 
persistent hepatitis C virus infection,” J. Exp. Med., vol. 197, no. 12, pp. 1645–
1655, Jun. 2003. 
[60] D. G. Bowen and C. M. Walker, “Adaptive immune responses in acute and 
chronic hepatitis C virus infection,” Nature, vol. 436, no. 7053, pp. 946–952, 
Aug. 2005. 
[61] L. Golden-Mason, A. E. L. Stone, K. M. Bambha, L. Cheng, and H. R. Rosen, 
“Race- and gender-related variation in natural killer p46 expression associated 
with differential anti-hepatitis C virus immunity,” Hepatology, vol. 56, no. 4, pp. 
1214–1222, Oct. 2012. 
[62] D. Sène et al., “Hepatitis C virus (HCV) evades NKG2D-dependent NK cell re-
sponses through NS5A-mediated imbalance of inflammatory cytokines,” PLoS 
Pathog., vol. 6, no. 11, p. e1001184, Nov. 2010. 
  
Abbreviations 
 
 
56 
 
7 Abbreviations 
ADCC  antibody dependent cell-mediated cytotoxicity 
AHC  acute hepatitis C 
aHCV  acute hepatitis C virus 
AIDS  acquired immune deficiency syndrome 
ALT   Alanine transaminase 
APC   Allophycocyanin 
AST   Aspartate transaminase 
BFA   Brefeldin A 
BSA  bovine serum albumine 
CD  cluster of differentiation 
CHC  chronic hepatitis C 
cHCV  chronic hepatitis C virus 
cm   centimetre 
DMEM Dulbecco's modified eagle's medium 
EDTA  Ethylenediaminetetraacetic acid 
E:T  Effector:target 
et al.  lat. et aliter 
FACS  fluorescence activated cell sorting 
FCS  fetal calf serum 
FITC   Fluorescein isothiocyanate 
FSC  forward scatter 
g   gravity (9,81 m/s2), gram 
h   hour 
HAART  highly active antiretroviral therapy 
HCC  hepatocellular carcinoma 
HCV  Hepatitis C virus 
HIV   human immunodeficiency virus 
HLA   human leukocyte antigen 
IFN  Interferon 
IL  Interleukin 
IU  international units 
K  Kilo 
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KIR  killer cell immunglobulin like receptors 
l   Litre 
LAMP-1 Lysosomal-associated membrane protein 1 
M  Molar 
m   Milli, Metre 
μ   Micro 
MACS magnetic activated cell sorter 
MHC  major histocompatibility complex 
MICA  MHC class I polypeptide-related sequence A 
MICB  MHC class I polypeptide-related sequence B 
Min  Minute 
MSM  men who have sex with men 
n  nano, number 
NCR  natural cytotoxicity receptors 
NEA  non-essential amino acids 
NK-cells  Natural killer cells 
NKT-cells  Natural killer T cells 
n.s.   not significant 
p   probability value 
PBMC peripheral blood mononuclear cells 
PBS  phosphate buffered saline 
PE  Phycoerythrin 
PerCP peridinin-chlorophyll-protein complex 
RBV  Ribavirin 
RFI  relative fluorescence intensity 
Rh  recombinant human 
RT  Room temperature 
S  Second 
SSC  side scatter 
TGF  transforming growth factor 
TNF  Tumor necrosis factor 
ULBP   UL16 binding protein 1 
WHO  World Health Organization 
°C   degree Celsius 
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